Sec Form 4 Filing - Heraud Benjamin @ ACUREN CORP - 2025-08-04

FORM 4 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0287 Expires: November 30, 2011 Estimated average burden hours per response... 0.5

1. Name and Address of Reporting Person Heraud Benjamin 2. Issuer Name and Ticker or Trading Symbol ACUREN CORP [ TIC] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X __ Director _____ 10% Owner X __ Officer (give title below) _____ Other (specify below) President and COO (Last) (First) (Middle) C/O ACUREN CORPORATION, 14434 MEDICAL COMPLEX DRIVE, SUITE 100 3. Date of Earliest Transaction (MM/DD/YY) 08/04/2025 (Street) TOMBALL, TX77377 4. If Amendment, Date Original Filed (MM/DD/YY) 6. Individual or Joint/Group Filing (Check Applicable Line) __ X __ Form filed by One Reporting Person _____ Form filed by More than One Reporting Person (City) (State) (Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 1.Title of Security (Instr. 3) 2. Transaction Date (MM/DD/YY) 2A. Deemed Execution Date, if any (MM/DD/YY) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4) Code V Amount (A) or (D) Price Common Stock 08/04/2025 A( 1 ) 115,465 A 115,465 ( 1 ) D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities) 1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (MM/DD/YY) 3A. Deemed Execution Date, if any (MM/DD/YY) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) 6. Date Exercisable and Expiration Date (MM/DD/YY) 7. Title and Amount of Underlying Securities (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4) Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares Restricted Stock Units ( 2 ) 08/04/2025 A 35,715 ( 3 ) ( 3 ) Common Stock 35,715 $ 0 35,715 D Performance Based Restricted Stock Units ( 4 ) 08/04/2025 A 35,714 ( 5 ) ( 5 ) Common Stock 35,714 $ 0 35,714 D

Reporting Owners Reporting Owner Name / Address Relationships Director 10% Owner Officer Other Heraud Benjamin C/O ACUREN CORPORATION 14434 MEDICAL COMPLEX DRIVE, SUITE 100 TOMBALL, TX77377 X President and COO Signatures /s/ MaryJo Obrien, Attorney-in-Fact 08/06/2025 Signature of Reporting Person Date

Explanation of Responses:

( 1 )On August 4, 2025, as a result of the mergers contemplated by that certain Agreement and Plan of Merger, dated as of May 14, 2025, by and among the Issuer, NV5 Global, Inc. ("NV5"), Ryder Merger Sub I and Ryder Merger Sub II (the "Merger Agreement"), 13,328 shares of common stock of NV5 and 157,716 restricted stock awards of NV5 (which were vested in full in accordance with their terms immediately prior to the effective time of the mergers and converted into the right to receive the Merger Consideration, less applicable tax withholdings)were converted into the right to receive 1.1523 shares of the Issuer's common stock ("Common Stock") per share, and $10.00 in cash per share, without interest (collectively, the "Merger Consideration"). Pursuant to the Merger Agreement, any outstanding restricted stock award of NV5 held by the Reporting Person automatically vested in full in accordance with its terms immediately prior to the effective time of the mergers. ( 2 )Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock. ( 3 )These restricted stock units vest on September 30, 2028. ( 4 )Each performance based restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock. ( 5 )These performance restricted stock units vest upon certain financial performance metrics of NV5 and to the extent earned will vest on September 30, 2026. The number of shares of Common Stock that will be earned is subject to decrease based on the results of the performance condition.

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.